Lör 22 jun / År 42 / Nr 3 2024

Innovation of imaging techniques, improved treatments and fun? How does that fit together?

To understand, we have approached the Swedish drug development innovator Antaros Medical, where Johannes Hulthe, the company’s CEO explained the connection very clearly: Scientific innovation can only arise from a boundless exchange between world class experts sharing passion, joint goals and having fun while doing a meaningful job. “It is actually not only important, it is a pre-requisite for us to provide high quality PET/MRI* services and partnerships for planning, design and execution of clinical imaging studies.”

Developing new medicines and treatments for patients is an expensive journey for any drug developer. Thanks to Antaros innovative imaging techniques and methods, pharmaceutical companies can benefit from improved understanding of human pathophysiology, examine effects of treatments at early stage and investigate which substances work and which don’t.

Such relatively quick access to high quality clinical data means bringing new medicines to patients in time, which is the ultimate strive that the entire Life Science world is sharing. “Antaros supports today a number of big pharmas, such as Sanofi, AstraZeneca and Bristol-Myers Squibb, but also smaller biotech companies. We focus on small to medium sized studies (15-150 patients) and we operate primarily in the cardiovascular and metabolic disease areas”, added Johannes.

Increasing collaborations and need for scientific services made Antaros growing rapidly from the 4 funders in August 2014 to today’s 27 life science professionals. Business and project management are being run from the BioVentureHub in Mölndal, while the R&D and Imaging corelab is operating from Uppsala. “Such strategic co-location with biotech and medtech companies provide unique opportunities to interact and advance pharmaceutical research – and a big portion of fun”, ended Johannes.

*PET/MRI = Positron Emission Tomography and Magnetic Resonance Imaging